CD8A and myeloid sarcoma: In addition to the abovementioned cells, over the last decade, research has shifted the focus of attention toward CD8+ T cells as evidence increasingly demonstrates that CD8+ T cells predominate over CD4+ T cells in CNS lesions of MS patients [52,53].